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Background: Vaccine against pertussis has been in use for several decades. Despite the widespread use of pertussis
vaccine, evidence shows resurgence of pertussis in high-income countries. Pertussis surveillance data is largely missing
from low- and middle-income countries (LMICs). Without data on trends of pertussis, it is difficult to review and amend
pertussis control policies in any country. We propose conducting a systematic review to evaluate the burden and trends
of pertussis in LMICs since 1974.
Methods/design: Common and medical subject heading (MeSH) terms for pertussis and LMICs will be used to
search electronic databases for the relevant literature published between 1974 and December 2014. Only studies
from LMICs that fulfils World Health Organisation (WHO) or CDC pertussis case definitions will be included. The
studies must have a clear numerator and denominator in a well-defined population.
Risk of bias will be evaluated by assessing all qualifying full-text articles for quality and eligibility using a modified
quality score assessment tool.
Standardised data extraction will be carried out after which descriptions of trends in the prevalence, incidence,
as well as mortality rate and case fatality rate, will be done. Where sufficient data is available, the results will be
stratified by age group, geography, location, vaccination and HIV status.
Discussion: The systematic review proposed by this protocol seeks to address the knowledge gap in the epidemiology
of pertussis in LMICs for the first time. It is anticipated that the background epidemiological trends of pertussis in LMICs
that our study will provide could be used in the planning for the control of pertussis.
Systematic review registration: PROSPERO CRD42015015159
Keywords: Pertussis, Whooping cough, Burden, Prevalence, Incidence, LMICsBackground
Pertussis or whooping cough is a highly infectious respira-
tory illness caused by Bordetella pertussis or Bordetella
parapertussis. Globally, the disease is notifiable in many
countries. Worldwide, the World Health Organisation
(WHO) estimates that 20 to 40 million annual cases of
pertussis and 300,000 deaths occur due to the disease, of* Correspondence: Rudzani.Muloiwa@uct.ac.za
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unless otherwise stated.which 90% occur in low- and middle-income countries
(LMICs) [1,2]. While good surveillance data support the
re-emergence of pertussis in high-income countries, per-
tussis surveillance data is largely missing for LMICs.
Therefore, trends in pertussis epidemiology in LMICs are
unknown [3,4]. To strengthen the existing strategies of
pertussis control in LMICs, it is critical to understand the
background epidemiology of the disease in these settings.
We are, therefore, conducting a systematic review to
evaluate the burden of pertussis in LMICs.
The availability of an effective vaccine against B. per-
tussis since the 1940s led to a substantial reduction inl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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1974, WHO included the whole cell vaccine (wP) in the
Expanded Programme on Immunization (EPI). The wP is
still widely used in many LMICs. However, in many high-
income countries, the original wP has been replaced with
various formulations of the acellular vaccine (aP), which
are believed to be equally effective and with an improved
safety profile compared to wP [6]. Some LMICs have also
introduced aP to their national EPI schedules [7]. In the
absence of complete pertussis epidemiology data in most
of the LMICs, positive or negative impacts resulting from
the introduction of aP will likely be missed. To improve
any vaccination programme, monitoring and evaluation
are crucial. A change in the epidemiology of a vaccine pre-
ventable disease is a key outcome in evaluation of a vac-
cination programme.
Epidemiological data from high-income countries
show that, despite high vaccine coverage with aP, per-
tussis burden has increased in non-immunised or par-
tially immunised infants [3,8]. Increasingly, in many
settings, pertussis is being recognised as an important
cause of morbidity in adolescents and adults, possibly
due to waning immunity. Older individuals have less
severe disease and fewer complications. However, older
persons have substantial economic costs associated
with unrecognised infection that may serve as an im-
portant source of infection for non-immune infants
[9-11]. Evidence is emerging that aP vaccines may not
have the same effectiveness or longevity of immunity as
the wP vaccines; this may partly explain the observed
re-emergence of pertussis in settings that have intro-
duced the aP [3,8]. As many other LMICs consider the
introduction of aP vaccines, understandably due to a
superior safety profile, the epidemiological data of per-
tussis in these settings will be more and more critical.
The burden and trends of pertussis are a challenge in
light of the difficulties in the diagnosis of the disease.
The diagnosis of pertussis is largely made on the basis
of the clinical picture. However, clinical presentation
may be modified by age, previous immunisation or in-
fection, antibiotic exposure and concurrent infection
with other pathogens [5]. The presentation of pertussis
is frequently atypical, especially in infants and adults
[5]. Laboratory confirmation of cases by serology, cul-
ture or PCR is thus very important. One of the main
reasons for lack of surveillance data in LMICs is ab-
sence of diagnostic facilities for confirmation of B. per-
tussis. This is compounded by a lack of standardised
clinical case definition and lack of resources to support
reporting of cases by health care workers [12]. Despite
these challenges, there are some data on the epidemi-
ology of the disease in a few LMICs that can be collated
to foster better understanding and a snapshot of the per-
tussis disease in these settings. Our aim is to synthesiseany available epidemiology data on pertussis in LMICs
and present a snapshot of the pertussis burden in these
settings. Our proposed systematic review will provide a
baseline understanding of the disease burden and trends
in LMICs.
Rationale
The current epidemiology of pertussis and its changing
pattern since the inception of the EPI in 1974 is poorly
understood in LMICs. There are valid concerns that re-
surgence of pertussis may be happening in LMICs with
possible future epidemics if no action is urgently taken.
The high HIV prevalence in LMICs coupled with sub-
optimal vaccines uptake are risk-modifying factors that
can fuel pertussis epidemics in these settings [13,14].
Objectives
To conduct a systematic review and meta-analysis of
studies assessing the prevalence of pertussis in LMICs
since the inception of the Expanded Programme on
Immunization (EPI) in 1974.
Primary objectives
1. To review available published literature on the
incidence and/or prevalence of pertussis in LMICs
since the inception of the EPI
2. To determine the trend in the incidence and/or
prevalence of pertussis in LMICs from 1974 to 2014
Secondary objectives
1. To investigate the impact of HIV infection on the
epidemiology of pertussis during the review period
2. To investigate the impact of vaccine coverage on the
burden of pertussis in LMICs
3. To describe the mortality rate and case fatality rate
ascribed to pertussis in LMICsMethods/design
Eligibility criteria
Types of participants
The review will include studies involving both children
and adults conducted in LMICs.Case definition
Studies will be considered for inclusion only if they
fulfil the pertussis case definitions recommended by
WHO or/and CDC [15,16] as shown in the following:
WHO pertussis case definition
Clinical case definition
♦A case diagnosed as pertussis by a physician or
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with at least one of the following symptoms: Paroxysms (that is, fits) of coughing
 Inspiratory whooping
 Post-tussive vomiting (that is, vomiting immediately
after coughing) without other apparent cause
Criteria for laboratory confirmation
♦ Isolation of Bordetella pertussis or
♦ Detection of genomic sequences by means of the
polymerase chain reaction (PCR) or
♦ Positive paired serology
Case classification
♦ Clinically confirmed: A case that meets the clinical
case definition but is not laboratory-confirmed
♦ Laboratory-confirmed: A case that meets the clinical
case definition and is laboratory-confirmed
CDC clinical case definition
Clinical Case Definition
In the absence of a more likely diagnosis a cough illness
lasting ≥2 weeks with one of the following symptoms:
♦ Paroxysms of coughing, OR
♦ Inspiratory ‘whoop, ’ OR
♦ Post-tussive vomiting, OR
♦ Apnea (with or without cyanosis) (FOR INFANTS
AGED < 1 YEAR ONLY)
Laboratory Criteria for Diagnosis
♦ Isolation of Bordetella pertussis from clinical
specimen
♦ Positive polymerase chain reaction (PCR) for B. pertussis
Epidemiologic Linkage




Meets the clinical case definition, is not laboratory-
confirmed, and is not epidemiologically linked to a
laboratory-confirmed case, OR
FOR INFANTS AGED <1 YEAR ONLY
♦ Acute cough illness of any duration with at least one
of the following signs or symptoms: Paroxysms of coughing, OR
 Inspiratory ‘whoop’, OR
 Posttussive vomiting, OR
 Apnea (with or without cyanosis)
AND♦ Polymerase chain reaction (PCR) positive for
pertussis, OR
FOR INFANTS AGED <1 YEAR ONLY:
♦ Acute cough illness of any duration with at least one
of the following signs or symptoms: Paroxysms of coughing, OR
 Inspiratory ‘whoop’, OR
 Posttussive vomiting, OR
 Apnea (with or without cyanosis)
AND
♦ Contact with a laboratory-confirmed case of pertussis
Confirmed
♦ Acute cough illness of any duration with isolation of
B. pertussis from a clinical specimen, OR
♦ Meets the clinical case definition AND is polymerase
chain reaction (PCR) positive for pertussis, OR
♦ Meets the clinical case definition AND had contact
with a laboratory-confirmed case of pertussis
*Note: An illness meeting the clinical case definition
should be classified as ‘probable’ rather than ‘confirmed’ if
it occurs in a patient who has contact with an infant aged
<1 year who is polymerase chain reaction (PCR) positive
for pertussis and has ≥1 sign or symptom and cough dur-
ation of <14 days.
Inclusion criteria
 Both adults and children will be included
 Clear diagnostic criteria
 All clinical and population studies with clear
denominator
Exclusion criteria
 Published before 1974 and after 2014
 Unclear denominator derivation
 Unclear diagnostic criteria
 Case reports
 Not conducted in LMICs
Outcomes
Primary outcomes
Prevalence or incidence of pertussis Incidence will be
defined as events of pertussis occurring over the total
period participants are at risk. Prevalence will be defined
as proportions of all participants suspected of pertussis
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participants fulfilling a clinical case definition.
Secondary outcomes
Secondary outcomes will include vaccination status, mor-
tality and case fatality rates associated with pertussis as
well as the HIV prevalence in the study settings of the
included studies.
Vaccination status will be classified as follows: unknown,
where no immunisation information is provided; unvaccin-
ated, where data indicates that no single vaccine dose has
been received; partially vaccinated, where data indicates an
incomplete primary schedule (less than three doses in the
first year of life); or fully immunised (completed primary
schedule with or without a booster dose).
Mortality will be defined as the proportion of deaths at-
tributable to pertussis in a study population as a propor-
tion of all deaths while case fatality will be defined as
mortality among confirmed or probable cases of pertussis.
Type of studies
Cross sectional, cohort and surveillance studies will be
included. Both prospective and retrospective studies will
be included. Inpatient, outpatient and population-based
studies will be included provided a denominator is avail-
able with explanation as to how it was derived.
The studies must have been conducted from 1974
until the end of 2014. The starting period was chosen as
it is the year in which WHO formally initiated the EPI.
Search strategy methods for the identification of studies
A comprehensive and sensitive search strategy has been
developed to identify relevant studies available from 1
January 1974 through 31 December 2014, regardless of
language or publication status (published, unpublished,
in press or in progress).
Several electronic databases will be searched for all the
relevant publications. Specifically the following databases
will be searched:







We will use both text words and medical subject head-
ing (MeSH) terms; for example, whooping cough OR per-
tussis, epidemiology, incidence and prevalence. These
terms will be combined with other relevant terms includ-
ing an African filter [17]. The literature search strategy willbe adapted for each database. Table 1 shows the search
strategy that we have developed for use in PubMed.
Selection of eligible studies
The primary author (RM) will screen the search outputs
using titles and abstracts. In addition, publication date,
study setting, study design, methods and patient popula-
tion as well as study outcomes will be evaluated. The
first and the second authors will then independently go
through the full text of all potentially eligible studies to
assess whether they meet the inclusion criteria. Discrep-
ancies in the list of included studies between the two
authors will be resolved through discussion and consen-
sus, with the assistance of the other two authors.
Data collection process
Data will be extracted from text, tables and figures and
recorded on a standardised form. Study investigators will
be contacted in cases of unclear data or eligibility cri-
teria. Among others, the following data will be extracted
from studies meeting our eligibility criteria:
 Study characteristics: period, design, objectives and
inclusion criteria
 Study population: country, setting, type of facility
and denominator
 Diagnostic methods: laboratory methods and clinical
case definitions
 Prevalence or incidence of pertussis: confirmed
cases and cases making clinical definition
 Pertussis patient characteristics: age and gender,
HIV status and pertussis vaccination status
 Pertussis deaths: mortality and case fatality rate
Risk of bias in individual studies
We will adapt the tool developed by Wasserman et al.
to assess the risk of bias as well as the quality of the in-
cluded studies (Table 2) [18]. This assessment criterion
is comprehensive and sufficient for the different types of
study designs that will be selected for inclusions. In
brief, specific variables will be examined to assess in-
ternal and external validity of the selected studies. The
tool takes into account the issues and principles dis-
cussed by Hoy et al. pertaining to internal and external
validity of prevalence studies [19].
Data synthesis
Data will be summarised using incidences and/or
prevalence.
The heterogeneity of the included studies will be
evaluated using the χ2-based Q statistic (significant for
P < 0.1) and the I2 statistic [20]. Where sufficient homo-
geneity (I2 statistic < 50%) between studies exists, the




#1 Pertussis (MeSH) OR whooping cough(MeSH)
#2 Bordetella pertussis OR B. pertussis OR Bordetella parapertussis OR B. parapertussis
#3 #1 OR #2
#4 Burden OR epidemiology OR incidence OR prevalence OR case*
#5 #3 AND #4
#6 (Angola OR Republic of Angola OR Albania OR Republic of Albania OR Algeria OR The People’s Democratic Republic of Algeria OR American Samoa OR Argentina OR Azerbaijan OR
Belarus OR Belize OR Bosnia and Herzegovina OR Bosnia-Herzegovina OR Bosnia OR Botswana OR Brazil OR Federative Republic of Brazil OR Bulgaria OR China OR People’s Republic
of China OR Colombia OR Costa Rica OR Fiji OR Gabon OR Gabonese Republic OR Grenada OR Hungary OR Islamic Republic of Iran OR Persia OR Iran OR Iraq OR Jamaica OR Jordan
OR Hashemite Kingdom of Jordan OR Kazakhstan OR Lebanon OR Lebanese Republic OR Libya OR State of Libya OR Macedonia OR Republic of Macedonia OR Malaysia OR Maldives
OR Republic of the Maldives OR Maldive Islands OR Marshall Islands OR Republic of the Marshall Islands OR Palau OR Republic of Palau OR Panama OR Republic of Panama OR Peru
OR Romania OR Serbia, OR the Republic of Serbia OR Seychelles OR the Republic of Seychelles OR South Africa OR Saint Lucia OR Saint Vincent and the Grenadines OR Suriname OR
Thailand OR Kingdom of Thailand OR Tonga OR Kingdom of Tonga OR Tunisia OR Turkey OR Turkmenistan OR Turkmenia OR Cuba OR Dominica OR Commonwealth of Dominica OR
The Dominican Republic OR Ecuador OR Mauritius OR Mexico OR United Mexican States OR Montenegro OR Namibia OR Tuvalu OR Ellice Islands OR Venezuela OR the Bolivarian
Republic of Venezuela)
#7 (Armenia OR armenia OR Bhutan OR Kingdom of Bhutan OR Bolivia OR Plurinational State of Bolivia OR Cameroon OR Republic of Cameroon OR Republic of Cameroun OR Cape
Verde OR Republic of Cape Verde OR Cote D’ivoire OR Ivory Coast OR Republic of Cote D’ivoire OR Djibouti OR Republic of Djibouti OR Arab Republic of Egypt OR Egypt OR El Salvador
OR Georgia OR Ghana OR Republic of Ghana OR Guatemala OR Republic of Guatemala OR Guyana OR Co-operative Republic of Guyana OR Honduras OR Republic of Honduras OR Spanish
Honduras OR Republic of Indonesia OR Indonesia OR India OR Republic of India OR Kiribati OR Republic of Kiribati OR Kosovo OR Kosovo and Metohija OR Laos OR Lao Lao People’s
Democratic Republic OR Lesotho OR Kingdom of Lesotho OR Mauritania OR Islamic Republic of Mauritania OR Micronesia, Fed. Sts. OR Federated States of Micronesia OR FSM OR Moldova
OR Republic of Moldova OR Mongolia OR Morocco OR Kingdom of Morocco OR Nicaragua OR Republic of Nicaragua OR Nigeria OR Federal Republic of Nigeria OR Pakistan OR Islamic
Republic of Pakistan OR Papua New Guinea OR Independent State of Papua New Guinea OR Paraguay OR Republic of Paraguay OR Philippines OR Republic of the Philippines OR Samoa
OR Independent State of Samoa OR Sao Tome and Principe OR Democratic Republic of Sao Tome and Principe OR Senegal OR Republic of Senegal OR Solomon Islands OR Sri Lanka OR
Democratic Socialist Republic of Sri Lanka OR Sudan OR Republic of the Sudan OR North Sudan OR Swaziland OR Kingdom of Swaziland OR Ngwane OR Yuwatini OR Syrian Arab Republic
OR Syria OR East Timor OR Timor-leste OR Democratic Republic of Timor-leste OR Ukraine OR Uzbekistan OR Republic of Uzbekistan OR Vanuatu OR Republic of Vanuatu OR Vietnam OR
the Socialist Republic of Vietnam OR West bank and Gaza OR Yemen OR Yemeni Republic OR Zambia OR Republic of Zambia)
#8 (Afghanistan OR Islamic Republic of Afghanistan OR Bangladesh OR People’s Republic of Bangladesh OR Benin OR Dahomey OR Republic of Benin OR Burkina Faso OR Burkina OR
Republic of Upper Volta OR Burundi OR Republic of Burundi OR Cambodia OR Kingdom of Cambodia OR Central African Republic OR Chad OR Republic of Chad OR Comoros OR Union
of the Comoros OR Democratic Republic of the Congo OR DR Congo OR Congo-Kinshasa OR DRC OR Zaire OR Eritrea OR State of Eritrea OR Ethiopia OR Federal Democratic Republic of
Ethiopia OR The Gambia OR Republic of the Gambia OR Guinea OR Republic of Guinea OR Guinea-Conakry OR Guinea-Bissau OR Republic of Guinea-Bissau OR Haiti OR Republic of Haiti
OR Kenya OR Republic of Kenya OR North Korea OR Democratic People’s Republic of Korea OR Kyrgyz Republic OR Kyrgyzstan OR Liberia OR Republic of Liberia OR Madagascar OR
Republic of Madagascar OR Malawi OR Republic of Malawi OR The Warm Heart of Africa OR Mali OR Republic of Mali OR Mozambique OR Republic of Mozambique OR Myanmar OR Burma
OR Republic of the Union of Myanmar OR Nepal OR Democratic Republic of Nepal OR Niger OR Republic of Niger OR Rwanda OR Republic of Rwanda OR Sierra Leone OR Republic of
Sierra Leone OR Somalia OR Federal Republic of Somalia OR South Sudan OR Republic of South Sudan OR Tajikistan OR Republic of Tajikistan OR Tanzania OR United Republic of Tanzania
OR Republic of Tanganyika and Zanzibar OR Togo OR Togolese Republic OR Uganda OR Republic of Uganda OR Zimbabwe OR Republic of Zimbabwe OR Rhodesia)
#9 #6 OR #7 OR #8














Table 2 Tool for assessment of quality and bias
Item Score
1. Study design (selection score)
a. Prospective clinical studies (any type)
♦ Consecutive enrolment 2
♦ Unspecified/random enrolment 1
b. Autopsy studies
♦ Consecutive enrolment 2
♦ Unspecified/random enrolment 1
c. Retrospective reviews (including subgroup analysis) 1
d. Review/editorial 0
e. Case report 0
2. Study objectives (selection score)
a. Clear inclusion criteria
♦ Aim related to pertussis prevalence or outcomes 3
♦ Related to OIs/general morbidity/respiratory
disease but not specific to pertussis
2
♦ Unrelated to clinical pertussis prevalence 1
b. Unclear inclusion criteria 1
3. Diagnosis* (quality of outcome ascertainment)
a. Laboratory-confirmed (any specified
method/specimen)
2
b. Clinical case definition (consistent with
WHO or CDC guidelines)
1
c. Not specified 0
4. Denominator
a. Raw data denominator 2
b. Calculated denominator 1
c. No/unclear denominator/investigated
< % of cohort for pertussis/exclusion group
0
5. Numerator (Pertussis numbers)
a. Raw data numerator 2
b. Calculated numerator 1
c. No/unclear numerator (clinical pertussis
not mentioned/tested)
0
6. Assessment of bias (low, high or unclear risk)
a. Attrition bias
♦ Amount, nature or handling of incomplete
outcome data
b. Selection bias
♦ Representativeness of the cases/cohort
(clear reasons for and rates of non-inclusion)
*Do not include data from clinical episodes of pertussis if no case definition
provided (even if study otherwise qualifies). CDC, Centers for Disease Control;
OI, opportunistic infection; WHO, World Health Organisation.
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Haenszel random effects model.
Subgroup analysis will be conducted based on the in-
come level of the country as defined by criteria set down
by the World Bank using the World Bank Atlas method(low, lower and upper middle-income countries) [21,22].
Other variables that will be considered for subgroup
analysis are age group, HIV status (if indicated), HIV
prevalence in the study country at the time of the study,
diagnostic criteria, period in which the study took place
and vaccination coverage as well as the location of the
study (hospital versus population based).
Proportions as percentages will be used to depict vac-
cination status, case fatality rate and HIV prevalence
while deaths per 100,000 population will be used to rep-
resent mortality rate.
The overall effect of study sample size on the study
outcomes will be assessed through sensitivity testing.
STATA software version 13 (STATA Corporation, Col-
lege Station, TX, USA) will be used to perform all the
statistical calculations.
The study will utilise the guidelines for reporting sys-
tematic reviews as set down by the revised 2009 PRISMA
statement. Findings in our systematic review will be pre-
sented in several ways. Flow diagrams will be used to sum-
marise the study selection process including a list of
excluded studies with reasons for exclusion. Tables for
both individual studies as well as for summaries of all in-
cluded studies will be used to present quantitative data.
Qualitative data such as assessment of quality of studies
and strength of evidence will be described in the text.
Discussion
Although high pertussis vaccination coverage has been
achieved in many countries, data from developed coun-
tries show that the pertussis burden, particularly among
adolescents and adults, has increased during the last
decade, and this presents an increased risk to infants
prior to complete vaccination [10]. In contrast, pertussis
burden in LMICs is less understood. For every country,
sound understanding of the trends in the burden of per-
tussis is required to assess the impact of current pertus-
sis control policies as well as decide on future policy
direction. We anticipate that results from our study will
provide a snapshot of the background epidemiological
trends of pertussis in LMICs. This information could be
used in disease control planning.
It is presumed that most of the burden of pertussis oc-
curs in LMICs [2]. However, there is no systematised
evidence of the burden of the disease as well as the impact
that vaccination against pertussis has had since the incep-
tion of EPI in 1974. Of concern, high-income countries
that routinely report the least burden of vaccine prevent-
able diseases have lately been reporting pertussis resur-
gence resulting in the review of disease control policies
[8,3]. It is likely that LMICs will also need a review of the
existing pertussis control programmes. The systematic
review and its envisaged meta-analysis that this protocol
proposes seek to address the knowledge gap in the
Muloiwa et al. Systematic Reviews  (2015) 4:62 Page 7 of 7epidemiology of pertussis in LMIC for the first time and
in a systematic approach.
Protocol registration
The protocol has been published in the PROSPERO




aP: acellular vaccine; EPI: Expanded Programme on Immunization;
HIV: human immunodeficiency virus; LMICs: low- and middle-income
countries; MeSH: medical subject heading; wP: whole cell vaccine.
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